IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

This trial is testing a new targeted cancer drug called IN10018 (a FAK inhibitor) in combination with standard chemotherapy, with or without an additional immunotherapy drug (KN046), for people with advanced pancreatic cancer that has not yet been treated with chemotherapy. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with advanced, locally advanced, or metastatic pancreatic ductal adenocarcinoma - You have not received any prior chemotherapy for your pancreatic cancer - You have at least one measurable tumor on scans - Your ECOG performance status is 0 or 1 (you are fairly active and independent) - Your organ function (bone marrow, liver, kidneys) meets requirements - You are not pregnant or breastfeeding **You may NOT be eligible if...** - You have had major surgery or a serious injury in the past 28 days - You have a known BRCA1 or BRCA2 gene mutation - You have had previous immunotherapy (PD-1/PD-L1/CTLA-4 targeted treatment) - You have received radical radiation in the past 3 months - You are currently taking strong medications that interact with the study drug Talk to your doctor to see if this trial is right for you.